29 news items
Page 2 of 2
is8bexgmvxtt68qqlkw
BMY
TSVT
5 Apr 24
in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile
l5bahu
BMY
TSVT
5 Apr 24
in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile
nr23u2u9
BMY
4 Apr 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
16lq0lub7thby dosapxpkvrgsjwjlj3svkkszklzrb47utt6r561gdl
BMY
2 Apr 24
).
Safety results were consistent with previous MDS studies, and progression to acute myeloid leukemia and total deaths were
fzzcjgrbaq4gjwu4oxgfx9iafvfxhs0aq8acbl6l5sny2d072rq2ly4
BMY
31 Mar 24
, regarding Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
hjrfe8vg5yx9k26ob1exvlvyu0g22wouzax
BMY
27 Mar 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
jlsia09tcra457fwadc48n6qdzfulcpruq
BMY
MRK
27 Mar 24
improved multiple secondary outcome measures, including reducing the risk of death from any cause or PAH clinical worsening events by 84% versus
0ny05rc00kyec0cxw
ATNM
AZN
BMY
25 Mar 24
-enlarging cysts that impair kidney function, potentially leading to kidney failure or premature death. Currently, an estimated 250,000 individuals
0udi1vc5ijqc3srlx6ny0w371t sdiexp3gxza4vcgpjol25au
BMY
23 Mar 24
CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial data submitted